<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089505</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5208</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <secondary_id>OCTANE</secondary_id>
    <nct_id>NCT00089505</nct_id>
  </id_info>
  <brief_title>NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission</brief_title>
  <acronym>OCTANE</acronym>
  <official_title>Optimal Combination Therapy After Nevirapine Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly included in anti-HIV
      drug regimens. However, HIV infected women who have previously taken the single dose NNRTI
      nevirapine (SD NVP) for the prevention of mother-to-child transmission (MTCT) of HIV may not
      respond as well to NNRTIs as women who have never taken NVP. Another class of anti-HIV drugs,
      protease inhibitors (PIs), may be more effective for women who have previously taken NNRTIs.
      This study will compare the effectiveness of NNRTI- and PI-based regimens in women who have
      taken NVP for prevention of MTCT of HIV. This study will also compare regimens including an
      NNRTI with regimens including a PI in women who have never taken NVP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NVP is the NNRTI of choice to prevent MTCT of HIV, especially in resource-limited settings.
      However, prolonged use of NVP may result in drug resistance, decreasing the efficacy of
      future anti-HIV regimens containing NVP. PIs are more expensive and cause different adverse
      effects than NNRTIs, but PI-containing regimens may be more effective than NNRTI-containing
      regimens in treating HIV infected women who previously took NVP for MTCT prophylaxis. This
      study will compare the efficacy of NNRTI- and PI-containing anti-HIV regimens in women who
      have previously taken NVP for MTCT of HIV and in women who have never taken NVP.

      The study will last a minimum of 48 weeks. Participants will be grouped by previous NVP
      exposure: participants who have previously taken NVP as MTCT prophylaxis (Trial 1
      participants), and participants who have never taken NVP (Trial 2 participants). Participants
      in each trial will be randomly assigned to one of two arms, NVP-containing arm(NVP/NVP for
      trial 1 participants and NoNVP/NVP for trial 2 participants) or PI-containing arm(NVP/LPV_r
      for Trial 1 participants and NoNVP/LPV_r for Trial 2 participants). At the start of the
      study, Arm NVP/NVP and NoNVP/NVP participants will receive emtricitabine (FTC) daily,
      tenofovir disoproxil fumarate (TDF) daily, and NVP daily for the first 14 days and then twice
      daily. Arm NVP/LPV_r and NoNVP/LPV_r participants will receive both FTC and TDF daily and
      lopinavir/ritonavir (LPV/RTV) twice daily. FTC and TDF may be replaced in either arm with the
      combination drug FTC/TDF.

      If participants experience virologic failure, toxicity, or otherwise cannot tolerate their
      regimens, they will switch to a different regimen. Arm NVP/NVP and NoNVP/NVP participants
      will switch to a regimen of two or more nucleoside reverse transcriptase inhibitors (NRTIs)
      and LPV/RTV; Arm NVP/LPV_r and NoNVP/LPV_r participants will switch to a regimen of two or
      more NRTIs and NVP. Study visits will occur at entry and at Weeks 2, 4, 8, 12, 16, 24, and
      then every 12 weeks thereafter. Visits will consist of a physical exam, medication
      assessment, and blood collection. Participants will be asked to complete adherence
      questionnaires at Weeks 4, 12, 24, and every 24 weeks thereafter, and quality of life
      questionnaires at Weeks 24 and ever 24 weeks thereafter. Study drugs will be provided for all
      participants through 48 weeks after the final participant is randomized.

      As per an amendment (dated April 13, 2009), participants will be asked to take part in an
      extension of this study. Enrollment in the extension is completely voluntary. The purpose of
      the extension is to monitor, in greater extent, the participants' health as they transition
      from study treatment to local, clinical care. During the study extension participants will
      not receive any medications through the study; it is expected that participants will receive
      their treatments through a local clinic.

      Participants enrolling in the extension will enter the extension at the same time as their
      last visit in the current study. For the extension, participants will be asked to come back
      to the clinic two times for study visits: at 12 and 72 weeks after entry into the extension.
      Because there will be a long time between these study visits, participants will also be
      contacted by phone (or through some other means) close to 48 weeks after entry into the
      extension.

      At each of these visits, participants will be asked about their health and medications,
      including current anti-HIV drugs. Participants will also be asked about any HIV care received
      outside of the study. As part of this study, investigators may need to review participants'
      non-study medical records and speak with their non-study care providers, to find out more
      about their HIV care and medical problems, and also to check results of lab tests.

      During the study extension period, participants will have blood drawn and also be tested for
      pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.</time_frame>
    <description>5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry</measure>
    <time_frame>Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.</time_frame>
    <description>5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Virologic Failure or Died.</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.</time_frame>
    <description>Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Who Experienced Virologic Failure or Died</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.</time_frame>
    <description>Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Count Change From Randomization</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.</time_frame>
    <description>Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.</time_frame>
    <description>The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced HIV-related Disease Progression or Death</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.</time_frame>
    <description>Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.</time_frame>
    <description>Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)&gt;=2.6 x ULN or alanine aminotransferase (ALT)&gt;=2.6 x ULN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month</measure>
    <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.</time_frame>
    <description>Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">745</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>NVP/NVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For participants who had SD NVP exposure prior to study entry. FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP/LPV_r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For participants who had SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NoNVP/NVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For participants who did NOT have SD NVP exposure prior to study entry.FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NoNVP/LPV_r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For participants who did NOT have SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>200 mg taken orally</description>
    <arm_group_label>NVP/NVP</arm_group_label>
    <arm_group_label>NVP/LPV_r</arm_group_label>
    <arm_group_label>NoNVP/NVP</arm_group_label>
    <arm_group_label>NoNVP/LPV_r</arm_group_label>
    <other_name>FTC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/Tenofovir disoproxil fumarate</intervention_name>
    <description>200/300 mg taken orally</description>
    <arm_group_label>NVP/NVP</arm_group_label>
    <arm_group_label>NVP/LPV_r</arm_group_label>
    <arm_group_label>NoNVP/NVP</arm_group_label>
    <arm_group_label>NoNVP/LPV_r</arm_group_label>
    <other_name>FTC/TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>400/100 mg taken orally</description>
    <arm_group_label>NVP/LPV_r</arm_group_label>
    <arm_group_label>NoNVP/LPV_r</arm_group_label>
    <other_name>LPV/RTV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>200 mg taken orally</description>
    <arm_group_label>NVP/NVP</arm_group_label>
    <arm_group_label>NoNVP/NVP</arm_group_label>
    <other_name>NVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>300 mg taken orally</description>
    <arm_group_label>NVP/NVP</arm_group_label>
    <arm_group_label>NVP/LPV_r</arm_group_label>
    <arm_group_label>NoNVP/NVP</arm_group_label>
    <arm_group_label>NoNVP/LPV_r</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for All Participants:

          -  HIV infected

          -  CD4 count less than 200 cells/mm^3 within 90 days prior to study entry

          -  Plasma HIV-1 RNA using standard Roche Amplicor HIV-1 Monitor Assay within 45 days
             prior to study entry

          -  the following laboratory values obtained within 45 days prior to study entry: absolute
             neutrophil count&gt;=750/mm^3;Hemoglobin&gt;=7.0g/dL;platelet count&gt;=50000/mm^3;aspartate
             aminotransferase (AST),Alanine aminotransferase (ALT), and alkaline phosphatase &lt;=2.5
             x ULN; total bilirubin &lt;=2.5 x ULN

          -  Normal renal function within 45 days prior to study entry

          -  Willing to use acceptable forms of contraception

          -  Karnofsky performance score &gt;=70 on at least one occasion within 45 days prior to
             study entry

          -  Parent or guardian willing to provide informed consent, if applicable

          -  Planning to remain in the same geographical area of residence and are willing to
             attend study visits as required

        Inclusion Criteria for Trial 1 Participants:

          -  Previously received NVP for prevention of MTCT of HIV

          -  Has documentation of all prior doses of NVP used for prevention of MTCT of HIV

          -  Last dose of NVP for prevention of MTCT of HIV taken at least 6 months prior to study
             entry

        Exclusion Criteria for All Participants:

          -  Previously received any antiretrovirals, excluding NVP for MTCT prophylaxis for Trial
             1 participants. Participants who have received up to 10 weeks of zidovudine alone and
             completed this course at least 6 months prior to study entry are not excluded.

          -  Use of systemic cancer chemotherapy, systemic investigational agents,
             immunomodulators, or rifampin within 30 days of study entry

          -  Pregnant or breastfeeding

          -  Known allergy or sensitivity to study drugs or their formulations

          -  Any condition, including drug or alcohol abuse, that, in the opinion of the
             investigator, may interfere with adherence to study regimens

          -  Serious illness requiring systemic treatment or hospitalization. Participants who
             complete therapy or are clinically stable on therapy for at least 30 days prior to
             study entry are not excluded.

          -  Tuberculosis (TB) treatment within 30 days prior to study entry

          -  Use of any prohibited medications within 30 days prior to study entry

          -  Involuntary incarceration in a correctional facility, prison, or jail for legal
             reasons or in a medical facility for treatment of either a psychiatric or physical
             illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahin Lockman, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital and Infectious Diseases Division, Department of Immunology and Infectious Diseases, Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederick Sawe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Walter Reed Project/WRAIR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Gaborone BHP Study Clinic</name>
      <address>
        <city>Bontleng</city>
        <state>Gaborone</state>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molepolole BHP Study Clinic, Scottish Livingstone Hospital</name>
      <address>
        <city>Bontleng Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moi University International Clnical Trials Unit</name>
      <address>
        <city>Eldoret</city>
        <zip>30100</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KMRI / Walter Reed Project Clinical Research Center</name>
      <address>
        <city>Kericho</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Project (UNC Project)</name>
      <address>
        <city>Lilongwe</city>
        <zip>(265) 175-5056</zip>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of KwaZulu Natal</name>
      <address>
        <city>Durban</city>
        <state>KZN</state>
        <zip>4013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital, Johannesburg</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre (JCRC)</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia (CIDRZ)</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe</name>
      <address>
        <city>Avondale</city>
        <state>Harare</state>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <reference>
    <citation>Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002 Apr-Jun;4(2):59-63. Review.</citation>
    <PMID>12152519</PMID>
  </reference>
  <reference>
    <citation>Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001 Oct 19;15(15):1951-7.</citation>
    <PMID>11600822</PMID>
  </reference>
  <reference>
    <citation>Harris M. Efficacy and durability of nevirapine in antiretroviral-experienced patients. J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S53-8. Review.</citation>
    <PMID>14562858</PMID>
  </reference>
  <reference>
    <citation>Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M; Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004 Jul 15;351(3):229-40. Epub 2004 Jul 9.</citation>
    <PMID>15247339</PMID>
  </reference>
  <reference>
    <citation>Nightingale S, Dabis F. Evidence behind the WHO guidelines: hospital care for children: what antiretroviral agents and regimens are effective in the prevention of mother-to-child transmission of HIV? J Trop Pediatr. 2006 Aug;52(4):235-8. Review.</citation>
    <PMID>16877674</PMID>
  </reference>
  <reference>
    <citation>Turner D, Wainberg MA. HIV transmission and primary drug resistance. AIDS Rev. 2006 Jan-Mar;8(1):17-23. Review.</citation>
    <PMID>16736948</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2004</study_first_submitted>
  <study_first_submitted_qc>August 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2004</study_first_posted>
  <results_first_submitted>August 30, 2010</results_first_submitted>
  <results_first_submitted_qc>January 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2011</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <keyword>MTCT</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited at 10 sites from 7 African countries: 3 from South Africa, 2 from Kenya, and 1 each in Botswana, Malawi, Uganda, Zambia and Zimbabwe, between November 2006 to July 2008. The Botswana site enrolled participants from two locations.</recruitment_details>
      <pre_assignment_details>HIV-infected, treatment-naive women, at least 13 years of age with CD4+ count&lt;200 cells/mm^3. Four participants were randomized but did not start treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NVP/NVP</title>
          <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
        </group>
        <group group_id="P2">
          <title>NVP/LPV_r</title>
          <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
        </group>
        <group group_id="P3">
          <title>NoNVP/NVP</title>
          <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
        </group>
        <group group_id="P4">
          <title>NoNVP/LPV_r</title>
          <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121">2 women never started treatment and per protocol, were not followed and not included in analysis.</participants>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="249">2 women never started treatment and per protocol, were not followed and not included in analysis.</participants>
                <participants group_id="P4" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112">The results for NVP/NVP were through database cutoff for DSMB review (by 6 October 2008).</participants>
                <participants group_id="P2" count="118">The results for NVP/LPV_r were through database cutoff for DSMB review (by 6 October 2008).</participants>
                <participants group_id="P3" count="228"/>
                <participants group_id="P4" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NVP/NVP</title>
          <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
        </group>
        <group group_id="B2">
          <title>NVP/LPV_r</title>
          <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
        </group>
        <group group_id="B3">
          <title>NoNVP/NVP</title>
          <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
        </group>
        <group group_id="B4">
          <title>NoNVP/LPV_r</title>
          <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="249"/>
            <count group_id="B4" value="251"/>
            <count group_id="B5" value="741"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="5"/>
                    <measurement group_id="B2" value="31" spread="5"/>
                    <measurement group_id="B3" value="35" spread="7"/>
                    <measurement group_id="B4" value="35" spread="8"/>
                    <measurement group_id="B5" value="33" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 13 and 19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 20 and 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 30 and 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="124"/>
                    <measurement group_id="B5" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 40 and 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="249"/>
                    <measurement group_id="B4" value="251"/>
                    <measurement group_id="B5" value="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zambia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Botswana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 count Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;50 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 50 to 99 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 100 to 149 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 150 to 199 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 200 to 249 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 250 to 299 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 300 to 349 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=350 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 count Continuous</title>
          <units>cell/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136" spread="60"/>
                    <measurement group_id="B2" value="135" spread="61"/>
                    <measurement group_id="B3" value="126" spread="68"/>
                    <measurement group_id="B4" value="125" spread="71"/>
                    <measurement group_id="B5" value="129" spread="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HIV-1 RNA Categorial</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 400 and 999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 1000 and 9,999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 10,000 and 99,999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 100,000 and 749,999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="128"/>
                    <measurement group_id="B5" value="375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=750,000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA Continuous</title>
          <units>log 10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" lower_limit="4.3" upper_limit="5.8"/>
                    <measurement group_id="B2" value="5.1" lower_limit="4.2" upper_limit="5.9"/>
                    <measurement group_id="B3" value="5.2" lower_limit="4.2" upper_limit="5.9"/>
                    <measurement group_id="B4" value="5.2" lower_limit="4.3" upper_limit="5.8"/>
                    <measurement group_id="B5" value="5.2" lower_limit="4.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WHO stage</title>
          <description>World Health Organization (WHO) produced WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents. It is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Clinical stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Virologic Failure or Died.</title>
        <description>Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.</time_frame>
        <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Virologic Failure or Died.</title>
          <description>Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
          <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Who Experienced Virologic Failure or Died</title>
        <description>Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.</time_frame>
        <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Experienced Virologic Failure or Died</title>
          <description>Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
          <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
          <units>Percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 percent of virologic failure or death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="16" upper_limit="31"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="14" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O4" value="14" lower_limit="9" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 percent of virologic failure or death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="21" upper_limit="40"/>
                    <measurement group_id="O2" value="12" lower_limit="5" upper_limit="20"/>
                    <measurement group_id="O3" value="17" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O4" value="20" lower_limit="14" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Count Change From Randomization</title>
        <description>Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.</time_frame>
        <population>Changes were calculated using the intent-to-treat approach (i.e. ignoring changes from randomized treatment) but no imputation was done for missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count Change From Randomization</title>
          <description>Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
          <population>Changes were calculated using the intent-to-treat approach (i.e. ignoring changes from randomized treatment) but no imputation was done for missing values.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48 CD4 count change from randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191" lower_limit="120" upper_limit="270"/>
                    <measurement group_id="O2" value="201" lower_limit="142" upper_limit="280"/>
                    <measurement group_id="O3" value="172" lower_limit="97" upper_limit="246"/>
                    <measurement group_id="O4" value="172" lower_limit="97" upper_limit="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96 CD4 count change from randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291" lower_limit="189" upper_limit="366"/>
                    <measurement group_id="O2" value="278" lower_limit="180" upper_limit="360"/>
                    <measurement group_id="O3" value="223" lower_limit="142" upper_limit="339"/>
                    <measurement group_id="O4" value="256" lower_limit="149" upper_limit="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.</title>
        <description>The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.</time_frame>
        <population>Numbers presented use as-treated method.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.</title>
          <description>The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
          <population>Numbers presented use as-treated method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="0.06" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="35" lower_limit="0.09" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced HIV-related Disease Progression or Death</title>
        <description>Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.</time_frame>
        <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced HIV-related Disease Progression or Death</title>
          <description>Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html</description>
          <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="0.01" upper_limit="0.09"/>
                    <measurement group_id="O2" value="4" lower_limit="0.01" upper_limit="0.07"/>
                    <measurement group_id="O3" value="19" lower_limit="0.04" upper_limit="0.11"/>
                    <measurement group_id="O4" value="26" lower_limit="0.05" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry</title>
        <description>5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.</time_frame>
        <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry</title>
          <description>5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
          <population>Numbers presented use the intent-to-treat approach (i.e. ignoring changes from randomized treatment).</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="O2" value="60" lower_limit="12" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O2" value="84" lower_limit="60">Not estimable as the upper limit for survival function at all weeks is above 90%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="24">Not estimable as the upper limit for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O2" value="NA">Not estimable as the estimates for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value was not adjusted for multiple interim analyses, but any adjustment would be negligible because Peto-Haybittle spending function was used as a basis for calculating the repeated confidence intervals used in interim monitoring.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The model was stratified by screening CD4 strata (&lt;50 vs. &gt;=50 cells/mm^3).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>7.61</ci_upper_limit>
            <estimate_desc>The HR is for NVP/NVP vs. NVP/LPV_r.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry</title>
        <description>5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
        <time_frame>Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.</time_frame>
        <population>The analysis was intent to treat per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry</title>
          <description>5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is &gt;=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF.</description>
          <population>The analysis was intent to treat per protocol.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="24" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O4" value="12" lower_limit="12" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="36" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="O4" value="36" lower_limit="12" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA" lower_limit="120">Not estimable as the estimate for survival function at all weeks is above 75%</measurement>
                    <measurement group_id="O4" value="132" lower_limit="96">Not estimable as the upper limit for survival function at all weeks is above 75%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>NoNVP/NVP regimen will be considered equivalent to the NoNVP/LPV_r regimen if the two-sided 95% confidence interval for the hazard ratio for virologi falure is entirely below 2.0; equivalence will be established if the same confidence interval is entirely within the range 0.5 to 2.0.</non_inferiority_desc>
            <p_value>0.43</p_value>
            <p_value_desc>P-value is for a test of superiority and was not adjusted for interim analyses, but any adjustment would be negligible because Peto-Haybittle spending function was used as a basis for calculating the repeated confidence intervals used.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>The cox proportional hazard model was stratified by screening CD4 strata (&lt;50 vs. &gt;=50 cells/mm3).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>The HR is for NoNVP/NVP vs. NoNVP/LPV_r.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality</title>
        <description>Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)&gt;=2.6 x ULN or alanine aminotransferase (ALT)&gt;=2.6 x ULN.</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.</time_frame>
        <population>Numbers presented use the as-treated approach.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality</title>
          <description>Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)&gt;=2.6 x ULN or alanine aminotransferase (ALT)&gt;=2.6 x ULN.</description>
          <population>Numbers presented use the as-treated approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month</title>
        <description>Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
        <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.</time_frame>
        <population>Numbers presented use as-treated approach.</population>
        <group_list>
          <group group_id="O1">
            <title>NVP/NVP</title>
            <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
          </group>
          <group group_id="O2">
            <title>NVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
          </group>
          <group group_id="O3">
            <title>NoNVP/NVP</title>
            <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
          </group>
          <group group_id="O4">
            <title>NoNVP/LPV_r</title>
            <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month</title>
          <description>Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used.</description>
          <population>Numbers presented use as-treated approach.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48 percent of full adherence in past month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 96 percent of full adherence in past month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms (with median follow-up: 72 weeks; range 0 -144 weeks). Throughout study for NoNVP/NVP and NoNVP/LPV_r arms (median follow-up: 72 weeks; range 0-180 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NVP/NVP</title>
          <description>For participants had single dose Nevirapine (SD NVP) exposure prior to study entry, Emtricitabine capsules(FTC) 200mg (1 capsule orally), Tenofovir disproxil fumerate (TDF) 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily in the morning for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive Lopinovir/Ritonovir (LPV/RTV)400/100mg (3 capsules orally) twice daily plus two more Nucleoside reverse transcriptase inhibitors (NRTIs). Following the review on 6 October 2008, the Data Safety Monitoring Board(DSMB) recommended release of the results from this arm.</description>
        </group>
        <group group_id="E2">
          <title>NVP/LPV_r</title>
          <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP 200mg (1 tablet orally) daily for 14 days before taking it twice daily. plus 2 more NRTIs. Following the review on 6 October 2008, the DSMB recommended release of the results from this arm.</description>
        </group>
        <group group_id="E3">
          <title>NoNVP/NVP</title>
          <description>For participants had NO SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally), TDF 300mg (1 tablet orally), and NVP 200mg (1 tablet orally) once daily for the first 14 days, then twice daily after 14 days. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV 400/100mg (3 capsules orally) twice daily plus two more NRTIs.</description>
        </group>
        <group group_id="E4">
          <title>NoNVP/LPV_r</title>
          <description>For participants had SD NVP exposure prior to study entry, FTC 200mg (1 capsule orally) and TDF 300mg (1 tablet orally) once daily and LPV/RTV 400/100mg (3 capsules orally) twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily 200mg (1 tablet orally) for 14 days before taking it twice daily plus 2 more NRTIs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fanconi syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain uppr</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Death neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Steve-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="225" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="227" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E4" events="251" subjects_affected="11" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E4" events="251" subjects_affected="15" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Vulvovaginal cadidiasis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Blookd albumin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Blood cholesterol abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" events="249" subjects_affected="11" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="251"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trial Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>(617) 432-2829</phone>
      <email>CBAR.ClinicalTrials.gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

